Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee Schwartzberg

Showing results (81-90 of 112) with videos related to

Pageof 12
Sort By:
Cancer Management and Research|June 6, 2017
APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trialIan D Schnadig, Richy Agajanian, Christopher Dakhil, et al.
Oncotarget|March 31, 2018
Correction: Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?Philip Carter, Costi Alifrangis, Biancastella Cereser, et al.
Oncotarget|March 7, 2018
Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?Philip Carter, Costi Alifrangis, Biancastella Cereser, et al.
Journal of Hospital Management and Health Policy|July 26, 2021
THRIVE intervention development: using participatory action research principles to guide a mHealth app-based intervention to improve oncology careJaneane N Anderson, Rebecca A Krukowski, Andrew J Paladino, et al.
Oncotarget|November 20, 2019
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm studySarina A Piha-Paul, Matthew H Taylor, Daniel Spitz, et al.
BMC Health Services Research|December 21, 2019
THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancerAndrew J Paladino, Janeane N Anderson, Rebecca A Krukowski, et al.
The Oncologist|December 17, 2022
Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later CyclesRudolph Navari, Gary Binder, Alex Molasiotis, et al.
Journal of Medical Case Reports|February 20, 2020
Unusual recurrent metastasizing benign breast papilloma: a case reportAmit L Jain, Janice Mullins, Justin R Smith, et al.
Health Communication|April 28, 2020
"Nobody Will Tell You. You've Got to Ask!": An Examination of Patient-Provider Communication Needs and Preferences among Black and White Women with Early-Stage Breast CancerJaneane N Anderson, J Carolyn Graff, Rebecca A Krukowski, et al.
Scientific Reports|March 12, 2021
Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomesAndrew Elliott, Michelle Saul, Jia Zeng, et al.
Pageof 12

Showing results (81-90 of 112) with videos related to

Sort By:
Pageof 12
Cancer Management and Research|June 6, 2017
APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trialIan D Schnadig, Richy Agajanian, Christopher Dakhil, et al.
Oncotarget|March 31, 2018
Correction: Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?Philip Carter, Costi Alifrangis, Biancastella Cereser, et al.
Oncotarget|March 7, 2018
Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?Philip Carter, Costi Alifrangis, Biancastella Cereser, et al.
Journal of Hospital Management and Health Policy|July 26, 2021
THRIVE intervention development: using participatory action research principles to guide a mHealth app-based intervention to improve oncology careJaneane N Anderson, Rebecca A Krukowski, Andrew J Paladino, et al.
Oncotarget|November 20, 2019
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm studySarina A Piha-Paul, Matthew H Taylor, Daniel Spitz, et al.
BMC Health Services Research|December 21, 2019
THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancerAndrew J Paladino, Janeane N Anderson, Rebecca A Krukowski, et al.
The Oncologist|December 17, 2022
Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later CyclesRudolph Navari, Gary Binder, Alex Molasiotis, et al.
Journal of Medical Case Reports|February 20, 2020
Unusual recurrent metastasizing benign breast papilloma: a case reportAmit L Jain, Janice Mullins, Justin R Smith, et al.
Health Communication|April 28, 2020
"Nobody Will Tell You. You've Got to Ask!": An Examination of Patient-Provider Communication Needs and Preferences among Black and White Women with Early-Stage Breast CancerJaneane N Anderson, J Carolyn Graff, Rebecca A Krukowski, et al.
Scientific Reports|March 12, 2021
Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomesAndrew Elliott, Michelle Saul, Jia Zeng, et al.
Pageof 12